Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.73 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.64 |
| ▸ | SQLE | Q14534 | 7/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | FNTA | P49354 | 1/20 | 0.52 |
| ▸ | FNTB | P49356 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23452103 | 1.00 | KMT2A (0.73) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL2780073 | 1.00 | KMT2A (0.73) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL2552456 | 1.00 | KMT2A (0.73) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL1219115 | 0.98 | KMT2A (0.68) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL10815851 | 0.98 | KMT2A (0.68) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL1219116 | 0.98 | KMT2A (0.68) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL8850002 | 0.86 | KMT2A (0.73) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL11290924 | 0.86 | KMT2A (0.73) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL23581543 | 0.86 | KMT2A (0.73) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL8013144 | 0.85 | KMT2A (1.00) | KMT2AALOX15MAPTMEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110268066-B | Enzymatic reaction medium containing surfactant | 诺华股份有限公司 | 2023-07-07 | — | — | CN | claimed |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | claimed |
| WO-2021158575-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| EP-1013652-B1 | Process for preparation of substituted chromanderivatives | BASF AG (DE) | 2002-08-14 | — | — | EP | claimed |
| US-6136986-A | REACTING SUBSTITUTED ACROLEIN COMPOUND WITH ACRYLATES, ACROLEINS, ACROLEIN ACETALS, ALLYL ALCOHOLS OR ALLYL ETHERS TO GIVE 3,4-DIHYDRO-2H-PYRANS, REACTING WITH ACID, FOLLOWED BY REACTING WITH SUBSTITUETED VINYL KETONE, DEHYDROGENATION | BASF AKTIENGESELLSCHAFT (DE) | 2000-10-24 | — | — | US | claimed |
| EP-1013652-A2 | Process for preparation of substituted chromanderivatives | BASF AKTIENGESELLSCHAFT (DE) | 2000-06-28 | — | — | EP | claimed |
| US-4073813-A | PLATINUM REDUCTION CATALYST, ALDEHYDES, HYDROGEN | RHONE-POULENC INDUSTRIES (FR) | 1978-02-14 | — | — | US | claimed |
| EP-3837247-B1 | SYNTHESIS OF CHROMANOL DERIVATIVES | BASF SE (DE) | 2024-06-05 | — | — | EP | disclosed |
| CN-110268066-B | Enzymatic reaction medium containing surfactant | 诺华股份有限公司 | 2023-07-07 | — | — | CN | disclosed |
| US-11673874-B2 | Synthesis of chromanol derivatives | BASF SE (DE) | 2023-06-13 | — | — | US | disclosed |
| WO-2023067040-A1 | PRECURSORS OF PHENOLIC FRAGRANT COMPOUNDS | GIVAUDAN SA (CH) | 2023-04-27 | — | — | WO | disclosed |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | disclosed |
| US-11220681-B2 | Enzymatic reaction medium containing surfactant | NOVARTIS AG (CH) | 2022-01-11 | — | — | US | disclosed |
| EP-0095133-A1 | Preparation of polyprenyl compounds or mixtures thereof | KURARAY CO., LTD. (JP) | 1983-11-30 | — | — | EP | disclosed |
| EP-0094666-A1 | Method of preparing polyprenyl compounds or mixtures thereof | KURARAY CO., LTD. (JP) | 1983-11-23 | — | — | EP | disclosed |
| US-4415741-A | REACTING O-HYDROXYACETOPHENONE AND CYCLOPENTANONE | BAYER AKTIENGESELLSCHAFT (DE) | 1983-11-15 | — | — | US | disclosed |
| US-4261988-A | ANTICHOLESTEROL AGENTS USED IN ANIMAL HUSBANDRY | BAYER AKTIENGESELLSCHAFT (DE) | 1981-04-14 | — | — | US | disclosed |
| US-4073813-A | PLATINUM REDUCTION CATALYST, ALDEHYDES, HYDROGEN | RHONE-POULENC INDUSTRIES (FR) | 1978-02-14 | — | — | US | disclosed |
| US-4026910-A | Oxidation process using nickel peroxide oxidizing agents | HOFFMANN-LA ROCHE INC. (US) | 1977-05-31 | — | — | US | disclosed |
| US-3994936-A | Catalytic rearrangement | HOFFMANN-LA ROCHE INC. (US) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | FABP2, FABP4, GUSB | KMT2A 4742/4885ALOX15 359/4885MAPT 3926/4885 |
| US-11673874-B2 | Synthesis of chromanol derivatives | CYP4A11, CYP51A1, CYP1A1 | KMT2A 977/4885ALOX15 2124/4885MAPT 4631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.